HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma.

AbstractPURPOSE:
Few studies have investigated the effects of everolimus therapy in Asian populations. This study evaluates the safety and efficacy of everolimus in Korean patients with metastatic renal cell carcinoma (mRCC).
METHODS:
We retrospectively reviewed records of Korean patients with mRCC (n = 22) who received everolimus between January 2009 and July 2010 and evaluated them for efficacy and safety.
RESULTS:
One patient achieved a partial response, and 16 patients had stable disease, corresponding to an overall response rate of 4.5 % and a disease control rate of 77.3 %. Median progression-free survival was 5.4 months (95 % CI 0.9-9.8). Median overall survival was not reached. Univariate analysis showed that Memorial Sloan-Kettering Cancer Center risk (P = .004), thrombocytopenia (P = .018), hyperglycemia (P = .007) and hypertriglyceridemia (P = .041) were associated with disease progression. The most common adverse events (AEs) were hypertriglyceridemia and anemia, similar to Western patients. Creatinine and aspartate aminotransferase levels were higher than those reported for Western patients. The most common grade ≥3 AEs in this study were hypertriglyceridemia and anemia, compared with lymphopenia (14 %) in Western patients.
CONCLUSIONS:
Safety of everolimus in Korean mRCC patients differed from that reported in Western patients. Therefore, liver function enzymes, hemoglobin levels, lipid profile and chest CT scans should be monitored more closely in Asian mRCC patients receiving everolimus.
AuthorsKi Hyang Kim, Sang Hyun Yoon, Hae-Jung Lee, Hyo Song Kim, Sang Joon Shin, Joong Bae Ahn, Sun Young Rha
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 72 Issue 4 Pg. 853-60 (Oct 2013) ISSN: 1432-0843 [Electronic] Germany
PMID23978988 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Everolimus
  • Sirolimus
Topics
  • Aged
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Asian Continental Ancestry Group
  • Carcinoma, Renal Cell (drug therapy, pathology)
  • Disease-Free Survival
  • Drug Monitoring (methods)
  • Everolimus
  • Female
  • Humans
  • Kidney Neoplasms (drug therapy, pathology)
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Republic of Korea
  • Retrospective Studies
  • Sirolimus (adverse effects, analogs & derivatives, therapeutic use)
  • Survival Rate
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: